Head to Head Comparison: Immix Biopharma (NASDAQ:IMMX) vs. Adherex Technologies (NASDAQ:FENC)

Adherex Technologies (NASDAQ:FENC) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Adherex Technologies and Immix Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1	1	4	1	2.71
Immix Biopharma	1	1	7	0	2.67

Adherex Technologies currently has a consensus price target of $15.40, indicating a potential upside of 46.81%. Immix Biopharma has a consensus price target of $20.67, indicating a potential upside of 86.02%. Given Immix Biopharma’s higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Adherex Technologies.

Profitability

This table compares Adherex Technologies and Immix Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Immix Biopharma	N/A	-73.24%	-59.20%

Insider and Institutional Ownership

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Adherex Technologies has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Earnings & Valuation

This table compares Adherex Technologies and Immix Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$51.00 million	7.18	-$9.74 million	($0.29)	-36.17
Immix Biopharma	N/A	N/A	-$29.44 million	($0.92)	-12.08

Adherex Technologies has higher revenue and earnings than Immix Biopharma. Adherex Technologies is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Adherex Technologies beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.